María Luisa De Mingo Dominguez1, Sonsoles Guadalix Iglesias1, Cristina Martin-Arriscado Arroba2, Begoña López Alvarez3, Guillermo Martínez Diaz-Guerra1, Jose Ignacio Martinez-Pueyo4, Eduardo Ferrero Herrero4, Federico Hawkins Carranza5,6. 1. Service of Endocrinology, University Hospital 12 de Octubre, Faculty of Medicine, University Complutense, Madrid, Spain. 2. Clinical Epidemiology & Research Institute i+12, University Hospital 12 de Octubre, Madrid, Spain. 3. Centro de Salud Goya, Madrid, Spain. 4. Endocrine Surgical Unit, University Hospital 12 de Octubre, Complutense University, Madrid, Spain. 5. Service of Endocrinology, University Hospital 12 de Octubre, Faculty of Medicine, University Complutense, Madrid, Spain. Federico.hawkins@salud.madrid.org. 6. Research Institute i+12, University Hospital 12 de Octubre, Madrid, Spain. Federico.hawkins@salud.madrid.org.
Abstract
The effect of thyroid suppression therapy (TST) on trabecular bone scores (TBS) and bone mineral density (BMD) in thyroidectomized women with differentiated thyroid carcinoma (DTC) on long-term follow-up is presently not conclusive. PATIENTS AND METHODS: We carried out a study in 61 premenopausal and 84 postmenopausal Caucasian women with DTC. Serum biochemistry, bone markers, TBS, BMD, and bone fractures were evaluated 1-3 months post surgery and after a median follow-up of 10 years. RESULTS: In the final study, patients belonged to Group I Premenopausal (n = 14) who remained in this status; Group II Premenopausal who became postmenopausal (n = 47); Group III patients who were and continued as postmenopausal (n = 84). Baseline premenopausal patients had a normal TBS mean value of 1.39 ± 0.14 significantly higher than that found in postmenopausal 1.31 ± 0.12 (p = 001). In the final study, premenopausal patients continued to have a normal TBS of 1.46 ± 0.08 compared to the significantly lower value of postmenopausal patients 1.25 ± 0.11 (p = 0.0009). Lumbar BMD (L-BMD) loss after the long-term study was significant in Group II (0.99 g/cm2 ± 0.13 vs. 0.91 ± 0.12 g/cm2, p < 0.0001) and there was a slight, but not significant, bone loss in Group I (1.00 ± 0.12 vs. 0.98 ± 0.11, p = 0.1936) and in Group III (0.86 ± 0.12 vs. 0.84 ± 0.15, p = 0.1924) compared with baseline values. CONCLUSION: Longer-term suppression therapy in female patients with DTC did not increase significantly the risk of bone loss, although we found in postmenopausal patients deterioration of bone microarchitecture. TBS study should be considered in the evaluation of postmenopausal DTC patients on long-term DTC for the evaluation of the risk of fractures.
The effect of thyroid suppression therapy (TST) on trabecular bone scores (TBS) and bone mineral density (BMD) in thyroidectomized women with differentiated thyroid carcinoma (DTC) on long-term follow-up is presently not conclusive. PATIENTS AND METHODS: We carried out a study in 61 premenopausal and 84 postmenopausal Caucasian women with DTC. Serum biochemistry, bone markers, TBS, BMD, and bone fractures were evaluated 1-3 months post surgery and after a median follow-up of 10 years. RESULTS: In the final study, patients belonged to Group I Premenopausal (n = 14) who remained in this status; Group II Premenopausal who became postmenopausal (n = 47); Group III patients who were and continued as postmenopausal (n = 84). Baseline premenopausal patients had a normal TBS mean value of 1.39 ± 0.14 significantly higher than that found in postmenopausal 1.31 ± 0.12 (p = 001). In the final study, premenopausal patients continued to have a normal TBS of 1.46 ± 0.08 compared to the significantly lower value of postmenopausal patients 1.25 ± 0.11 (p = 0.0009). Lumbar BMD (L-BMD) loss after the long-term study was significant in Group II (0.99 g/cm2 ± 0.13 vs. 0.91 ± 0.12 g/cm2, p < 0.0001) and there was a slight, but not significant, bone loss in Group I (1.00 ± 0.12 vs. 0.98 ± 0.11, p = 0.1936) and in Group III (0.86 ± 0.12 vs. 0.84 ± 0.15, p = 0.1924) compared with baseline values. CONCLUSION: Longer-term suppression therapy in female patients with DTC did not increase significantly the risk of bone loss, although we found in postmenopausal patients deterioration of bone microarchitecture. TBS study should be considered in the evaluation of postmenopausal DTC patients on long-term DTC for the evaluation of the risk of fractures.
Entities:
Keywords:
Bone mineral density; Differentiated thyroid cancer; TSH suppression therapy; Trabecular bone score
Authors: G Pioli; M Pedrazzoni; E Palummeri; M Sianesi; R Del Frate; P P Vescovi; M Prisco; V Ulietti; D Costi; M Passeri Journal: Acta Endocrinol (Copenh) Date: 1992-03
Authors: Laura Y Wang; Andrew W Smith; Frank L Palmer; R Michael Tuttle; Azhar Mahrous; Iain J Nixon; Snehal G Patel; Ian Ganly; James A Fagin; Laura Boucai Journal: Thyroid Date: 2014-12-16 Impact factor: 6.568
Authors: Eduardo Kanterewicz; Emma Puigoriol; Pilar Peris; Luis Del Río; Pau Rosique; Aina Yáñez Journal: Med Clin (Barc) Date: 2009-09-25 Impact factor: 1.725
Authors: D S Cooper; B Specker; M Ho; M Sperling; P W Ladenson; D S Ross; K B Ain; S T Bigos; J D Brierley; B R Haugen; I Klein; J Robbins; S I Sherman; T Taylor; H R Maxon Journal: Thyroid Date: 1998-09 Impact factor: 6.568
Authors: M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti Journal: J Endocrinol Invest Date: 2020-07-21 Impact factor: 4.256
Authors: B É C A Sousa; B C Silva; T de Oliveira Guidotti; M C Pires; M M S Soares; A M Kakehasi Journal: J Endocrinol Invest Date: 2021-03-17 Impact factor: 4.256
Authors: Chae Won Chung; Hoon Sung Choi; Sung Hye Kong; Young Joo Park; Do Joon Park; Hwa Young Ahn; Sun Wook Cho Journal: J Clin Med Date: 2021-05-03 Impact factor: 4.241